Clinical Trial

Surveillance of Pancreatic Health After Diabetes Diagnosis

Study acronym: SAFE-D
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes within the last 6 months. Participants will: * attend 3 study visits over 12 months time * provide a blood sample at each study visit * complete an anxiety questionnaire at each visit.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-27; most recent amendment 2026-03-20.
Status change: Not Yet Recruiting → Recruiting 2025-08-22
Trial Details
NCT Number NCT06803771
Lead Sponsor University Hospital Southampton NHS Foundation Trust
Collaborators: ClearNote Health
Conditions Diabetes Mellitus, Pancreatic Cancer, Adult
Enrollment 15,000 participants
Start Date 2025-05-21
Primary Completion 2028-02-28 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-03-23